Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.
Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.
复制标题
长期血液透析患者中的晚期糖基化末端产物（SRAGE）和S100A12（SRAGE）（SRAGE）（SRAGE）（SRAGE）（S100A12（EN-RAGE））之间的关联。
DOI：
10.3346/jkms.2017.32.1.54
复制
发表时间：
2017-01
影响因子：
4.5
通讯作者：
Jung JY
中科院分区：
文献类型：
--
作者：
Jung ES;Chung W;Kim AJ;Ro H;Chang JH;Lee HH;Jung JY
血液透析(HD)患者会经历血管钙化，最终导致高死亡率。此前，我们报道了晚期糖基化终产物可溶性受体(SRAGE)和细胞外新发现的RAGE结合蛋白S100A12(EN-RAGE)与血管钙化的关系。在这里，我们扩大了我们的观察范围，调查这些生物标志物是否有助于预测这些受试者的心血管发病率和死亡率。因此，我们评估了SRAGE和S100A12与长期血液透析患者死亡率的关系。这是一项对199名HD患者进行的前瞻性观察队列研究，来自我们先前研究的扩展分析。对血浆sRAGE、S100A12、合并症等传统危险因素进行调查。在多变量分析中，使用COX比例风险回归对累积死亡率进行评估。观察期44个月。观察期内死亡27例(13.6%)。单因素分析显示，S100A12与糖尿病(P=0.040)、超敏C反应蛋白(HsCRP)相关(P=0.006)。在多变量分析中，血浆sRAGE(危险比[HR]=1.155；95%可信区间[CI]=0.612~2.183；P=0.656)和S100A12(HR=0.960；95%CI=0.566~1.630；P=0.881)与HD患者的死亡率无关，尽管传统的死亡率预测因素包括年龄、心血管疾病史以及血清白蛋白和超敏C反应蛋白水平与死亡率有关。死亡的有力预测因子是年龄、心血管疾病和白蛋白水平。血浆sRAGE和S100A12可能是预测HD患者全因死亡率的弱替代标志物，尽管S100A12部分与糖尿病和炎症有关。
Hemodialysis (HD) patients experience vascular calcification, ultimately leading to high mortality rates. Previously, we reported associations between soluble receptor for advanced glycation end products (sRAGEs) and extracellular newly identified RAGE-binding protein S100A12 (EN-RAGE) and vascular calcification. Here, we extended our observations, investigating whether these biomarkers may be useful for predicting cardiovascular morbidity and mortality in these subjects. Thus, we evaluated the relationship between sRAGE and S100A12 and mortality in long-term HD patients. This was a prospective observational cohort study in 199 HD patients from an extended analysis of our previous study. Plasma sRAGE, S100A12, comorbidities, and other traditional risk factors were investigated. The cumulative incidences for death using Cox proportional hazards regression were evaluated in multivariable analyses. The observation period was 44 months. During the observation period, 27 (13.6%) patients died. Univariate analysis demonstrated that S100A12 was correlated with diabetes (P = 0.040) and high-sensitivity C-reactive protein (hsCRP) (P = 0.006). In multivariable analyses, plasma sRAGE (hazard ratio [HR] = 1.155; 95% confidence interval [CI] = 0.612–2.183; P = 0.656) and S100A12 (HR = 0.960; 95% CI = 0.566–1.630; P = 0.881) were not associated with mortality in HD patients, although traditional predictors of mortality, including age, history of cardiovascular diseases (CVDs), and serum levels of albumin and hsCRP were related to mortality. Powerful predictors of mortality were age, CVD, and albumin levels. Plasma sRAGE and S100A12 may be weak surrogate markers for predicting all-cause mortality in patients undergoing HD, although S100A12 was partly related to diabetes and inflammation.